Get the Stockscreener App
11.38
81.50%
5.11
After Hours:
11.17
-0.21
-1.85%
Verve Therapeutics Inc stock is traded at $11.38, with a volume of 83.82M.
It is up +81.50% in the last 24 hours and up +145.79% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$6.27
Open:
$11.035
24h Volume:
83.82M
Relative Volume:
18.17
Market Cap:
$569.18M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-4.3938
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
+78.23%
1M Performance:
+145.79%
6M Performance:
+102.85%
1Y Performance:
+115.94%
1-Day Range:
$10.85
$11.40
1-Week Range:
$5.88
$11.40
52-Week Range:
$2.8647
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
11.38 | 569.18M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini
Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More Movers - Barron's
Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks
Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks
Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha
5 Analysts Assess Verve Therapeutics: What You Need To Know - Benzinga
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum - Daily Chhattisgarh News
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol (NYSE:LLY) - Seeking Alpha
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - Yahoo Finance
Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade) - Seeking Alpha
Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more - CNBC
Why Verve Therapeutics Stock Is Skyrocketing Today - MSN
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - Yahoo Finance
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com
Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus
Lilly-Verve deal sends gene editing stocks higher - MSN
Stocks to Watch Tuesday: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - TradingView
Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday - Benzinga
Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit
Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. - MSN
Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize
Verve Therapeutics gets snapped up by Eli Lilly for $1.3B - Axios
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN
Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg.com
Verve Therapeutics downgraded to Hold from Buy at Canaccord - TipRanks
Eli Lilly agrees to acquire Verve Therapeutics for $1 billion, starting tender offer - MLex
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters
Biotech Stock Surging on Billion-Dollar Buyout - Schaeffer's Investment Research
Verve Therapeutics Stock: Decoding a Massive 73% Surge - Daily Chhattisgarh News
Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News
Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’ By Stocktwits - Investing.com India
William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisition by Eli Lilly | VERV Stock News - GuruFocus
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - MSN
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily
Lilly to acquire Verve Therapeutics for up to $1.3 billion - Investing.com
Morning Brew: Eli Lilly's Acquisition Boosts Verve Therapeutics - GuruFocus
Lilly to acquire Verve Therapeutics - The Pharma Letter
This Stock Just Jumped 80%. Eli Lilly Is Closing in on a $1.3 Billion Bid, Says Report. - MSN
Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News
Lilly spends $1B on Boston biotech developing gene-editing cholesterol drug - The Business Journals
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '25 |
Sale |
4.15 |
2,777 |
11,525 |
17,420 |
| Ashe Andrew D. | See Remarks |
Apr 02 '25 |
Sale |
4.15 |
2,681 |
11,126 |
348,828 |
| Politi Jason | Chief Technical Ops. Off. |
Apr 02 '25 |
Sale |
4.15 |
3,235 |
13,425 |
14,226 |
| Dorval Allison | Chief Financial Officer |
Apr 02 '25 |
Sale |
4.15 |
3,350 |
13,903 |
13,280 |
| Lister Troy | Chief Scientific Officer |
Apr 02 '25 |
Sale |
4.15 |
2,189 |
9,084 |
6,952 |
| Dorval Allison | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.64 |
555 |
3,130 |
5,380 |
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):